Weekly HIV Regimen Meets Phase 3 Goal
The investigational combination pairs islatravir and lenacapavir in a once-weekly single-tablet regimen.
-
By
-
Kathryn Wighton
-
June 10, 2026
-
Clinical Scorecard: Weekly HIV Regimen Meets Phase 3 Goal
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Islatravir inhibits HIV-1 replication through multiple mechanisms; Lenacapavir acts at multiple stages of the HIV life cycle. |
| Target Population | |
| Care Setting | |
Key Highlights
- Phase 3 ISLEND-1 and ISLEND-2 trials met primary efficacy endpoints at week 48.
- Investigational regimen of islatravir and lenacapavir was statistically noninferior to standard daily therapy.
- Safety profile of the investigational regimen was comparable to comparator regimens.
- No new safety concerns were identified in both studies.
Guideline-Based Recommendations
Diagnosis
Management
- Switching to once-weekly islatravir/lenacapavir is investigational and not yet approved.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with virologically suppressed HIV
Combination of islatravir and lenacapavir is investigational and shows promise for once-weekly dosing.
Clinical Best Practices
Related Resources & Content
